Targacept, Inc.

Targacept, Inc. (Targacept) is a biopharmaceutical company engaged in the design, discovery, and development of neuronal nicotinic receptor (NNR) therapeutics for the treatment of diseases and disorders of the central nervous system. The company currently focuses on developing a robust portfolio of multiple clinical-stage product candidates, as well as preclinical programs, with significant medical need and commercial potential. The company is headquartered in North Carolina, the US.The company reported revenues of (U.S. Dollars) USD 20.09 million during the fiscal year ended December 2008, an increase of 73.52% over 2007. The operating loss of the company was USD 28.14 million during the fiscal year 2008, as compared to an operating loss of USD 31.77 million during 2007. The net loss of the company was USD 25.66 million during the fiscal year 2008, as compared to a net loss of USD 28.07 million during 2007.

Street: 
200 East First Street
City: 
Winston-Salem
Postcode: 
27101
Federal State : 
United States
WebSite: 
www.targacept.comwtpageindex
Fax: 
1-336-4802107

Company Index Score

Current Index Score Historical Index Score
  • Targacept, Inc. currently scores 50 % in the index.
  • Targacept, Inc. is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Targacept, Inc. is currently ranked 1 out of 4535 companies. This is in the top 0.022 % percent of Pharmaceutical companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets